



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WQ66-G609  
Silver Spring, MD 20993-0002

APR 22 2011

Ms. Jennifer Bolton, RAC  
Regulatory Affairs Manager  
Boston Scientific Corp.  
One Scimed Place  
Maple Grove, MN 55311

Re: P100023  
ION™ Paclitaxel-Eluting Coronary Stent System (Monorail and Over-The-Wire Systems)  
Filed: June 17, 2010  
Amended: November 17, November 19, and December 10, 2010; January 31, February  
22, and March 29, 2011  
Procode: NIQ

Dear Ms. Bolton:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the ION™ Paclitaxel-Eluting Coronary Stent System. This device is indicated for improving luminal diameter for the treatment of de novo lesions in native coronary arteries  $\geq 2.25$  mm to  $\leq 4.00$  mm in diameter in lesions  $\leq 34$  mm in length. We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device and insofar as the sale and distribution of the device are restricted to practitioners. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for this device has been established and approved at 18 months.

Continued approval of this PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. Two copies of this report, identified as "Annual Report" and

bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

You have agreed to provide annual stability data for your Maple Grove manufacturing site as part of your annual reports.

In addition to the Annual Report requirements, you must provide the following data in post-approval study reports (PAS). Two copies, identified as "PMA Post-Approval Study Report" and bearing the applicable PMA reference number, should be submitted to the address below.

1. You should collect and report to the Agency on an annual basis, clinical outcomes through 5 years post-procedure on at least 80% of patients enrolled (excluding those discontinued due to death) in the PERSEUS Workhorse and PERSEUS Small Vessel studies. When appropriate or as requested by FDA, you should submit PMA supplements requesting approval to update your Instructions for Use (IFU) to include these data.
2. You should collect clinical data on the implantation of the PMA-approved, commercially distributed ION product in the U.S. The trial should be statistically powered to evaluate the annual rates of stent thrombosis, and the rate of cardiac death plus myocardial infarction (MI) through five years in patients treated with the ION product according to its labeled indications. These data are needed to evaluate whether the rate of stent thrombosis plateaus or increases over time, and to evaluate the impact of stent thrombosis on rates of cardiac death and MI. These data are also needed to evaluate the potential for rare adverse events related to the drug substance and/or drug carrier that could not be detected in your initial clinical trials.

You have proposed collecting these data from at least 2,500 patients at up to 50 U.S. sites in the ION Postmarket Registry. FDA agrees that the registry protocol submitted in the original PMA is acceptable. Please provide progress reports at 6, 12, 18, and 24 months and annually thereafter through 5 years with data from your U.S. registry. When appropriate or as requested by FDA, you should submit PMA supplements requesting approval to update your IFU to include these data. Please note that if subsequent data analyses identify areas of significant off-label use, you should submit an IDE to conduct an appropriate study to evaluate the off-label use.

3. The issue of the optimal duration of dual antiplatelet therapy following PCI with drug-eluting stents (DES) remains a critical question that is currently being studied in the DAPT trial. FDA acknowledges that you are participating in this trial to address a condition of approval for the Taxus Liberte DES (P060008). As the duration of dual antiplatelet therapy is also relevant for the ION Paclitaxel-Eluting Coronary Stent, you should fulfill your commitment to the condition of PMA approval for P060008. When appropriate or as requested by FDA, you should submit PMA supplements to the ION PMA (P100023) requesting approval to update your IFU to include the data collected in the DAPT trial. If you do not fulfill the condition of approval for P060008, you should conduct or participate in a separate clinical trial that will develop data to study the duration of dual antiplatelet therapy following implantation of the ION DES and subsequently submit PMA supplements to this PMA requesting approval to include these data in a IFU update.

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA.

Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" ([www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm)).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at [www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm](http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm).

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at [www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm](http://www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm).

CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at [www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm). Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all approved labeling in final printed form. Final printed labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

Page 5 – Ms. Jennifer Bolton, RAC

All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing. One of those three copies may be an electronic copy (eCopy), in an electronic format that FDA can process, review and archive (general information:


<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm134508.htm>; clinical and statistical data:

<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm136377.htm>)

U.S. Food and Drug Administration  
Center for Devices and Radiological Health  
PMA Document Mail Center – WO66-G609  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Ms. Pharoah Garma at (301) 796-6345 or at [pharoah.garma@fda.hhs.gov](mailto:pharoah.garma@fda.hhs.gov).

Sincerely yours,



Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health